Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you

recruiting
3 975
countries
28
conditions
2 106

22 trials match your criteria

Hormone-refractory prostate cancer

Recruiting

Study of AMO959, lutetium (177Lu) vipivotide tetraxetan, and a drug combination for adults with advanced prostate cancer.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone

Hormone-dependent prostate cancer

Recruiting

Study on the Effects of Darolutamide and Drug Combination for Patients with Metastatic Hormone-Naïve Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone

Prostate cancer metastatic+1

Recruiting

Study on the Effect of Degarelix on Prostate-Specific Membrane Antigen in Patients with Untreated Metastatic Prostate Cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Degarelix

Hormone-refractory prostate cancer

Recruiting

Study on Darolutamide and Radiation Therapy for Patients with Castration-Resistant Prostate Cancer and Oligometastases

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide

Prostate cancer

Recruiting

Study on High-Risk Prostate Cancer Treatment Using Darolutamide, Relugolix, and Drug Combination for Eligible Patients

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide

Prostate cancer+1

Recruiting

Study on How Degarelix and Drug Combination Affect Gut Health in Patients with Prostate Cancer or Benign Prostate Hyperplasia

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Degarelix

Hormone-dependent prostate cancer

Recruiting

Study on the Effectiveness of Triptorelin, Goserelin Acetate, and Enzalutamide in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Degarelix

Compulsive sexual behaviour

Not yet recruiting

Comparing cognitive behavioral therapy alone versus cognitive behavioral therapy combined with degarelix to prevent sexual offenses in patients with paraphilic disorders

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Degarelix

Prostate cancer+1

Not yet recruiting

Study on Darolutamide, Triptorelin, and Leuprorelin Acetate for Patients with Newly Diagnosed Prostate Cancer and Pelvic Lymph Node Metastases

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide

Prostate cancer

Not yet recruiting

Study on Docetaxel and Carboplatin-Docetaxel Combination for Prostate Cancer Patients Progressing After Olaparib Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Hormone-dependent prostate cancer

Not recruiting

Study of luxdegalutamide and abiraterone combination in adult men with metastatic hormone-sensitive prostate cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone

Prostate cancer metastatic

Not recruiting

Study of Debio 4228 for Patients with Advanced or Metastatic Prostate Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Degarelix

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.